Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SUMMER INFAN | SUMR | 8.43% |
| SCIENTIFIC L | SCIL | 8.00% |
| FEDERAL MOGU | FDML | 5.91% |
| NATUS MEDICA | BABY | 5.62% |
| RADIANT LOGI | RLGT | 5.32% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Comerica Inc. ( CMA - Analyst Report ) remains committed to increase shareholders’ wealth and plans to buy back shares up to $375 million between the first quarter of 2012 and the first quarter of 2013. This announcement follows the company’s clearance of the stress test.
Notably, the Federal Reserve reviewed Comerica’s capital plan under a stressed economic scenario and made no objection to the capital distributions considered in it. Along with the share buyback activity, the plan also includes a 50% hike in its quarterly dividend to 15 cents per share from 10 cents. Comerica’s board will review this dividend increase proposal at its April 24, 2012 meeting.
Besides the dividend hike, Comerica’s capital plan comprises the authority for redemption of its remaining $25 million of trust preferred securities when callable. We believe Comerica’s passing of the stress test along with its capital distribution plan is a testament of the company’s solid capital position.
Besides Comerica, the other Wall Street banks such as JPMorgan Chase & Co. ( JPM - Analyst Report ) , Wells Fargo & Company ( WFC - Analyst Report ) and U.S. Bancorp ( USB - Analyst Report ) have also increased their dividends and share buybacks following the Fed’s approval of their capital plans.
Our Take
Going forward, we believe that continuous geographic diversification beyond the company’s traditional and slower-growing Midwest markets could drive growth over the next cycle. Capital deployment efforts also inspire investors’ confidence in the stock.
Notably, Comerica commenced a share repurchase program that, combined with dividend payments, resulted in a total payout to shareholders of 47% of 2011 net income. In fact, the share buyback amount represents a solid increase over the $110 million the company repurchased in 2011.
We believe that the company’s current capital position allows sufficient scope for further capital deployment. Yet, its significant exposure to riskier areas such as commercial real estate markets, unsettled economic environment and regulatory issues are concerns.
Shares of Comerica currently carry a Zacks #2 Rank, which translates into a short-term Buy rating.
Read the full Analyst Report on CMA
Read the full Analyst Report on JPM
Read the full Analyst Report on USB
Read the full Analyst Report on WFC